Background: Allergic bronchopulmonary aspergillosis (ABPA) is a persistent problem for many cystic fibrosis (CF) patients. It is a challenging condition to diagnose and manage.
This is then weaned down on the basis of IgE levels, chest radiography, spirometry, and pulmonary symptoms, ideally within in Symptoms: Increased wheeze, cough, production of dark sputum plugs, fever, malaise, and general deterioration.
Other features: Pulmonary deterioration that is not responding to antibacterial treatment; pulmonary infiltrates, mucoid impaction or central bronchiectasis on chest radiography; an elevated serum immunoglobulin E (IgE) (> 1000 IU/mL); presence of specific IgE anti-A. fumigatus; and elevated eosinophil count. The patient may have a positive skin-prick test result to A. fumigatus allergen.
 Acute or subacute clinical deterioration (cough, wheeze, exercise intolerance, exerciseinduced asthma, change in pulmonary function, or increased sputum production) not attributable to another aetiology. There were no exclusion criteria used.
Results

Demographics
Of the 87 patients with CF, 20 (23%) had previously been diagnosed with ABPA. 60%
of the cohort were boys. Table 2 . Distribution of exacerbations Figure 1 and Table 2 show data on the number of exacerbations experienced by each patient. Table 1 shows a summary of the demographic data. Ages are rounded to the last month. IgE between 500 IU/mL and 1000 IU/mL, and 11 (55%) had an IgE below 500 IU/mL. 
Diagnosis
Prednisolone prescribing
All patients were started on prednisolone once diagnosed. Mean starting dose mg/kg (excluding those given max dose)
(± 0.53)
No. given at maximum 40 mg 7
Number given at > 2 mg/kg 1 Number given at 1.50-1. 99 5 Number given at 1.0-1. 49 4 Number given at < 1 mg/kg1 patient was prescribed voriconazole due to itraconazole intolerance. Figure 5 displays the results of antifungal drug level monitoring.
Figure 5. Antifungal drug level results
In patients who had an unsatisfactory antifungal medication level, the dose was changed and levels repeated until a satisfactory level was recorded.
Discussion
Key findings
This audit studied a population of patients 
Itraconazole prescribing
It is stated in guidelines that itraconazole levels must be measured due to varying rates of absorption in children, and to prevent liver damage due to excess levels. The team should discuss how to improve monitoring of itraconazole levels to prevent children from either being below therapeutic levels, or having high levels and risking liver damage.
Changes implemented
After presenting the conclusion and patients remaining on itraconazole had their levels measured within the last year. This is still an area which needs improvement and it is recommended that all patients on itraconazole should be recalled for levels at the next clinic.
Learning points
What is already known?
 ABPA is a challenging condition for patients and for clinicians who manage it.
 Diagnostic criteria are difficult to define, with many patients not fitting the full criteria, despite responding positively to ABPA therapy.
 There are guidelines on how to manage ABPA effectively, as published by the Cystic Fibrosis Trust.
What this study adds
 Insight into the demographics of patients who have been diagnosed with ABPA in CF in the Mersey area.
 Further information on diagnostic criteria to be used in the discussion of how to define ABPA.
 Recommendations on the consistency of prednisolone dosing, based on existing guidelines.
 Recommendations on the importance of improving the consistency of itraconazole monitoring, based on guidelines and studies into the toxicology of the drug.
